




Minor iridoids (veronicoside and minecoside), phenolics (picein and androsin (7)) and several cucurbitacin glycosides have also been isolated. The cucurbitacin glycosides isolated are 2- β -glucosyloxy-3,16,20,25-tetrahydroxy-9-methyl-19-norlanosta-5,23-dien-11,22-dione (8); 2- β -glucosyloxy-16,20,22-trihydroxy-9-methyl-19-norlanosta-5,24-dien-3,11-dione (9); Arvenin III (10); 25-acetyloxy-2- β -D-glucopyranosyloxy-3,16-dihydroxy-9-methyl-19-norlanosta-5,23-dione (11); 25-acetyloxy-2- β -D-glucopyranosyloxy-3,16,20-trihydroxy-9-methyl-19-norlanosta-5-en-22-one; 2- β -D-glucopyranosyloxy-3,16,20-trihydroxy-9-methyl-19-norlanosta-5,24-dien-22-one; 2- β -D-glucopyranosyloxy-3,16-dihydroxy-4,4,9,14-tetramethyl-19-norpregn-5-en-20-one; 2,3,16,20,25-pentahydroxy-9-methyl-19-norlanosta-5-en-22-one; 2-(6-o-cinnamoyl- β -D-glucopyranosyloxy)-3,16,20,25-tetrahydroxy-9-methyl-19-norlanosta-5-en-22-one (8,11,12).



10. Arvenin III



11

Several cucurbitacins with unusual side chains have been reported by Stuppner and Muller. These are (2 β , 3 β , 9 β , 10 α , 16 α , 20 ϵ , 24 ϵ)-20,24-epoxy-2-(β -D-glucopyranosyloxy)-3,16,25-trihydroxy-9-methyl-19-norlanosta-5-en-11-one; (2 β , 9 β , 10 α , 16 α , 20 ϵ , 24 ϵ)-20,24-epoxy-2-(β -D-glucopyranosyloxy)-16,25-dihydroxy-9-methyl-19-norlanosta-5-en-3,11-dione; (2 β , 9 β , 10 α , 16 α , 20 ϵ , 24 ϵ)-20,24-epoxy-2-(β -D-glucopyranosyloxy)-16,25,26-trihydroxy-9-methyl-19-norlanosta-5-en-3,11-dione; (2 β , 3 β , 9 β , 10 α , 16 α , 20 ϵ , 24 ϵ)-20,24-epoxy-2-(β -D-glucopyranosyloxy)-3,16,25,26-trihydroxy-9-methyl-19-norlanosta-5-en-11-one; (2 β , 9 β , 10 α , 16 α , 20 ϵ , 24 ϵ)-20,24-epoxy-2-(β -D-glucopyranosyloxy)-16,20,25-trihydroxy-9-methyl-19-norlanosta-5,24-dien-3,11-dione and (2 β , 9 β , 10 α , 16 α , 20 ϵ , 24 ϵ)-20,24-epoxy-2-(β -D-glucopyranosyloxy)-3,16,20,26-tetrahydroxy-9-methyl-19-norlanosta-5,24-dien-11-one (13). The iridoid glycoside fraction, named as 'Picroliv' has also been isolated and been tested for various biological activities (14).

Pharmacological Activities

Hepatoprotective activity

P. kurroa and Picrolive are investigated in great deal for the hepatoprotective activity. Picoside II and related glycosides have been shown to protect liver against intoxication by carbon tetrachloride in mice (15). Kutkin also possesses the hepatoprotective activity against liver damage induced by galactosamine in rats and against the damage induced by *Plasmodium berghei* in mastomys (16).

Hepatoprotective activity of Picroliv has been studied against various hepatotoxic agents like paracetamol,

alcohol-carbon tetrachloride, thioacetamide, galactosamine, ethanol, aflatoxin B₁ and rifampicin (17, 18, 19, 20, 21, 22, 23, 24, 25). Picroliv when given orally to rats 6 - 12 mg/kg for 7 days caused significant reversal of the paracetamol induced biochemical changes which include changes in activities of γ -glutamyl transpeptidases, 5'-nucleotidase, succinate dehydrogenase, glucose-6-phosphatase, cytochrome P₄₅₀ and contents of glycogen and cholesterol in liver. Picroliv was also found to reverse the biochemical changes induced by thioacetamide, galactosamine, aflatoxin B₁, oxytetracycline, alcohol-carbon tetrachloride, rifampicin and ethanol (14, 17, 22, 26). One report suggested that the hepatoprotective activity is due to kutkin and kutkin free fractions are devoid of any activity (16).

Recent reports show that picroliv also prevents the renal ischemia-reperfusion-injury in rats and picroliv preconditioning protects the rat liver against ischemia-reperfusion injury (27, 28).

In clinical studies on patients of infective hepatitis with jaundice, *P. kurroa* led to a rapid fall in serum bilirubin levels towards normal range and quicker clinical recovery with no untoward effect (29).

Anti-inflammatory activity

Kutkin, Picoside I and Kutkoside possess dose dependant anti-inflammatory activity in several acute and chronic test models (30). In adjuvant induced and formaldehyde arthritis in rats and mice, kutkin, Picoside I and Kutkoside were shown to possess significant activity. In carrageenan induced oedema, inhibitory activity was remarkably enhanced upon intra peritoneal treatment in rats. It also inhibited the acetic acid induced vascular permeability in mice and leukocyte migration in rats. Kutkin lacked analgesic, antipyretic or ulcerogenic effect (30). The anti-inflammatory activity is reported to be mediated by a non-neural augmentation of β -adrenoceptor function or consequent cellular events (31, 32, 33). However, recent report shows that the extracts of *P. kurroa* have cyclooxygenase-2 (COX-2) inhibitory activity (34).

Hypolipidaemic activity

Picroliv in albino rats has shown hypolipidaemic activity in normal as well as in triton- and cholesterol-fed rats. Serum lipids were lowered by picroliv (25 mg/kg body weight) in triton WR-1339 induced hyperlipemia. Chronic feeding (6 mg/kg) in normal rats and in animals simultaneously treated with cholesterol (25 mg/kg) for 30 days caused lowering in the lipid and protein levels constituting β -lipoproteins followed by an increase in high density lipoprotein cholesterol in experimental animals. Picroliv altered the lipolytic activities in plasma, liver, heart and adipose tissues and stimulated receptor mediated catabolism of low density lipoproteins. The lipid lowering action is mediated through inhibition of cholesterol biosynthesis in liver, increased faecal bile acid excretion and enhanced

plasma lecithin:cholesterol acyl transferase activity (35). In another study, the extracts produced marked reduction in serum cholesterol and coagulation time (36).

Immunostimulant activity

The ethanolic extract showed potent immunostimulatory activity, stimulating both cell-mediated and humoral immunity (37). It also stimulated phagocytosis in experimental animals without producing mitogenic activity (38). The alcoholic extract was shown to inhibit the mast cell anaphylaxis. Mast cell-IgE binding, assessed from induction of passive sensitisation was not affected. Calcium independent early activation events in mast cell anaphylaxis indicated the inhibitory influence of Picrorhiza kurroa treatment. It also inhibits the membrane protease release. Thus, it was suggested that Picrorhiza kurroa act as immunostimulant through the alteration of membrane structure function (33).

Oral administration of Picroliv (10 mg/kg for 7 days) in mice prior to immunisation with sheep red blood cells (SRBC) was found to significantly increase hemagglutinating antibody (HA) titre, plaque forming cells (PFC) and delayed hypersensitivity response to SRBC. Picroliv also enhances the non-specific immune response characterised by an increase in macrophage migration index (MMI), (¹⁴C) glucosamine uptake, phagocytosis of (¹⁴C) leucine labelled E. coli, chemiluminescence of peritoneal macrophages and higher uptake of [³H] thymidine in the lymphocytes of treated mice (39). Picroliv also selectively augmented human T cell response to mycobacterial protein antigens suggesting it can be used as adjunct to chemotherapy (40).

Antioxidant activity

Picroliv, Picoside I and Kutkoside were studied for their antioxidant activity. These inhibited the non-enzymatic generation of superoxide anion as studied in Phenazine/NADH system. Similarly, it also inhibits the superoxide anion generation in xanthin - xanthine oxidase system and the MDA generation in rat liver microsomes stimulated with ascorbate-ferric system. Thus the activity of these glycosides is like that of superoxide dismutase, metal ion chelators and xanthine oxidase inhibitors (41). The extract of *P. kurroa* has also been reported to have free radical scavenging activity, reducing the hydrogen peroxide-induced cytotoxicity and DNA damage in human non-immortalized fibroblasts. The extracts show a dose-dependent free radical scavenging capacity and a protective effect on DNA cleavage (42).

Antiasthmatic activity

Picrorhiza extracts have beneficial results in management of bronchial asthma (43). Through different chemical and pharmacological methods, phenol glycoside - androsin - was shown to be the active compound preventing allergen and platelet-activating factor induced bronchial obstruction *in vivo* (10 mg/kg,

per oral, 1 hr prior to inhalation challenge) (12). Study of molecular mechanisms suggest that picroliv may act as a protective agent against hypoxia/reoxygenation induced injuries and the mechanism underlying such protection involves a novel signal transduction pathway evidenced by reduction in Protein Kinase C (PKC) and inhibition of protein tyrosine kinase (44).

Anti-allergic effect

Picroliv has anti-allergic and anti-anaphylactic activity. It inhibited passive cutaneous anaphylaxis in mice and rats and protected mast cells from degranulation in a concentration dependant manner independent of histamine receptor blocking activity (45).

Antileishmanial activity

Picroliv was studied for protective effect against *Leishmania donovani* infections in *Mesocricetus auratus* and showed significant antileishmanial activity (39, 46).

Anticancer activity

Cancer chemoprevention of chemically induced tumours by Picroliv, has been studied on 20-methylcholanthrene (20-MC)-induced sarcoma model and 7,12-dimethylbenz[α]-anthracene (DMBA)-initiated papilloma formation in BALB/c mice. Picroliv at the dose of 100 and 200 mg/kg, p.o inhibited the sarcoma development and exhibited anti-tumour-promoting activity on a two-stage carcinogenesis test on mouse skin using DMBA as an initiator and croton oil as a promoter (47).

Summary

Picrorhiza kurroa is a widely used medicinal plant in traditional and folklore medicine. The main chemical constituents that have been studied in great detail and found to possess the various pharmacological activities are the glycosides, mainly the iridoid glycosides. Picroliv, the standardised glycoside fraction shows most of the activities entitled for the drug. The plant has hepatoprotective, anti-inflammatory, antilipidaemic, immunostimulant, antiallergic and antiasthmatic activity. The plant has the potency and may thus be explored further to the clinic level.

References

1. K. R. Kirtikar and B. D. Basu, Indian Medicinal Plants. International Book Distributors, Dehra Dun (1987), pp. 1487-1489
2. B. P. Subedi, *Himalayan Bioresources*, 1, 4-12 (2000)
3. R. P. Rastogi, V. N. Sharma and S. Siddiqui, *J. Sci. & Ind. Res.*, **8B**, 173-8 (1949).
4. R. P. Rastogi, A. B. Sen and M. L. Dhar, *Bull. Natl. Inst. Sci. India*, **4**, 47-57 (1955).
5. R. P. Rastogi and M. L. Dhar, *J. Sci. and Ind. Res.*, **18B**, 219-25 (1959).
6. I. Kitagawa, K. Hino, T. Nishimura, E. Mukai, I. Yoshioka, H. Inouye and T. Yoshida, *Tetrahedron Lett.*, **43**, 3837-40 (1969).
7. B. Singh, and R. P. Rastogi, *Ind. J. Chem.*, **10(1)**, 29-31 (1972).
8. H. Stuppner and H. Wagner, *Planta Med.*, **55(5)**, 467-9 (1989).

9. Q. Jia, M. F. Hong and D. Minter, *J. Nat. Prod.*, **62(6)**, 901-3 (1999).
10. W. A. Laurie, D. McHale and J. B. Sheridan, *Phytochem.*, **24(11)**, 2659-61 (1985).
11. H. Stuppner, H. Kaehling, D. Seligmann and H. Wagner, *Phytochem.*, **29(5)**, 1633-37 (1990).
12. H. Stuppner, E. D. Mueller and H. Wagner, *Phytochem.*, **30(1)**, 305-10 (1991).
13. H. Stuppner and E. P. Mueller, *Phytochem.*, **33(5)**, 1139-45 (1993).
14. B. N. Dhawan, *Med. Chem. Res.*, **5(8)**, 596-605 (1995).
15. V. J. Ram, *Drug News Perspect.*, **14(6)**, 353-63 (2001).
16. R. A. Ansari, B. S. Aswal, R. Chander, B. N. Dhawan, N. K. Garg and N. K. Kapoor, *Ind. J. Med. Res.*, **87**, 401-4 (1988).
17. Y. Dwivedi, R. P. Rastogi, S. K. Sharma, N. K. Garg and B. N. Dhawan, *Planta Med.*, **57(1)**, 25-8 (1991).
18. Y. Dwivedi, R. P. Rastogi, R. Mehrotra, N. K. Garg and B. N. Dhawan, *Pharmacol. Res.*, **27(2)**, 188-9 (1993).
19. A. Santra, S. Das, A. Maity, S. B. Rao and D. N. Muzumder, *Ind. J. Gastroenterol.*, **17(1)**, 6-9 (1998).
20. B. Saraswat, P. K. Visen, G. K. Patnaik and B. N. Dhawan, *J. Ethnopharmacol.*, **66(3)**, 263-9 (1999).
21. B. Saraswat, P. K. Visen, G. K. Patnaik and B. N. Dhawan, *Ind. J. Exp. Biol.*, **35(12)**, 1302-5 (1997).
22. S. Saxena, R. Rastogi, N. K. Garg and B. N. Dhawan, *Drug Dev. Res.*, **33(1)**, 46-50 (1994).
23. B. Shukla, P. K. Visen, G. K. Patnaik and B. N. Dhawan, *Planta Med.*, **57(1)**, 29-33 (1991).
24. P. K. Visen, B. Saraswat and B. N. Dhawan, *J. Pharmacol. Toxicol. Methods*, **40(3)**, 173-9 (1999).
25. R. Rastogi, A. K. Srivastava, M. Srivastava, and A. K. Rastogi, *Planta Med.*, **66(8)**, 709-13 (2000).
26. S. C. Tripathi, G. K. Patnaik and B. N. Dhawan, *Ind. J. Pharmacol.*, **23(3)**, 143-8 (1991).
27. P. Seth, R. Kumari, S. Madhavan, A. K. Singh, H. Mani, K. K. Banuadha, S. C. Sharma, D. K. Kulshreshtha and R. K. Maheshwari, *Biochem. Pharmacol.*, **59(10)**, 1315-22 (2000).
28. A. K. Singh, H. Mani, P. Seth, J. P. Gaddipati, R. Kumari, K. K. Banuadha, S. C. Sharma, D. K. Kulshreshtha and R. K. Maheshwari, *Eur. J. Pharmacol.*, **395(3)**, 229-39 (2000).
29. G. N. Chaturvedi, R. H. Singh, *Curr. Med. Pract.*, **9**, 451-4 (1965).
30. G. B. Singh, B. D. Gupta, S. Bani, S. Singh, A. Khajuria, M. L. Sharma and S. R. Bannerjee, *Phytotherapy Res.*, **7(6)**, 402-7 (1993).
31. B. L. Pandey and P. K. Das, *Ind. J. Physiol. Pharmacol.*, **32(2)**, 120-5 (1988).
32. B. L. Pandey and P. K. Das, *Indian J. Physiol. Pharmacol.*, **33(1)**, 28-30 (1989).

33. B. L. Pandey and P. K. Das, *Indian J. Physiol. Pharmacol.*, **32(4)** : 289-292 (1988).
34. Y. Zhang, D. L. Dewitt, S. Murugesan and M. G. Nair, *Life Sci.*, 2005 (Epub ahead of print).
35. A. K. Khanna, R. Chander, N. K. Kapoor and B. N. Dhawan, *Phytother. Res.*, **8(7)**, 403-7 (1994).
36. N. S. Tewari and P. C. Jain, *J. Res. Ayur. Siddha*, **1(1)**, 121-4 (1980)
37. C. K. Atal, M. L. Sharma, A. Kaul and A. Khajuria, *J. Ethnopharmacol.*, **18(2)**, 133-41 (1986).
38. M. L. Sharma, C. S. Rao and P. L. Duda, *J. Ethnopharmacol.*, **41(3)**, 185-92 (1994)
39. A. Puri, R. P. Saxena, P. Y. Guru, O. K. Kulshreshtha, D. K. Saxena and B. N. Dhawan, *Planta Med.*, **58(6)**, 528-32 (1992).
40. S. Sinha, J. Mehrotra, L. Bala, A. K. Jaiswal and B. N. Dhawan, *Immunopharmacol. Immunotoxicol.*, **20(4)**, 579-88 (1998).
41. R. Chander, N. K. Kapoor and B. N. Dhawan, *Biochem. Pharmacol.*, **44(1)**, 180-3 (1992).
42. A. Russo, A. A. Izzo, V. Cardile, F. Borrelli and A. Vanella, *Phytomedicine*, **8(2)**, 125-32 (2001).
43. D. Rajaram, *Bombay Hosp. J.*, **18 (2)**, 14-18 (1976).
44. J. P. Gaddipati, S. Madhavan, G. S. Sidhu, A. K. Singh, P. Seth and R. K. Maheshwari, *Mol. Cell Biochem.*, **194(1-2)**, 271-81 (1999).
45. C. C. Baruah, P. P. Gupta, L. G. Patnaik and B. N. Dhawan, *Pharmacol. Res.*, **38(6)**, 487-92 (1998).
46. N. Mittal, N. Gupta, S. Saxena, N. Goyal, U. Roy and A. K. Rastogi, *Life Sci.*, **63(20)**, 1823-34 (1998).
47. N. V. Rajesh Kumar and R. Kuttan, *Teratog. Carcinog. Mutagen*, **21(4)**, 303-13 (2001).